Product
Classification System
The single most consequential skill in FDA regulatory consulting. Before any registration, any application, any label review — you must classify the product correctly. Wrong classification means wrong center, wrong pathway, wrong forms, wrong fees, and wrong timeline. Everything downstream depends on getting this right first.
Why Classification Is the Most Important Skill
Every FDA regulatory pathway begins with a single question: what kind of product is this? The answer determines which of FDA's five centers has jurisdiction, which forms you file, what fees you pay, what timelines you face, what data you must generate, and what you can legally say about the product on its label and in marketing.
Getting classification wrong in either direction is expensive. Classifying a drug as a food means your client ships an unapproved drug into the U.S. — triggering import detention, possible seizure, and potential criminal liability. Classifying a food as a drug means your client spends millions and years on clinical trials for a product that needed only a facility registration. Both directions are disasters.
What makes classification genuinely difficult — and genuinely valuable as a consulting skill — is that it is not determined by what a product is made of. It is determined by what the product is intended to do. This single principle, called the intended use doctrine, creates a vast gray zone where the same physical product can be a food, a drug, a cosmetic, or a supplement depending entirely on how it is presented to the consumer.
Intended Use Determines Classification — Always
FDA's statutory definition of a drug includes products "intended to affect the structure or any function of the body" (21 U.S.C. § 321(g)(1)). This means the same compound — say, melatonin — can be classified differently based solely on how it is marketed. Sold as a "sleep support supplement" → dietary supplement. Sold as "treatment for insomnia" → unapproved drug. The physical product is identical. The classification — and the entire regulatory pathway — is completely different.
The Intended Use Doctrine — The Foundation of Classification
FDA establishes intended use from multiple sources — not just the label. This is one of the most important and most misunderstood aspects of FDA regulation. Courts have consistently held that FDA can look beyond the physical label to establish intended use.
Sources of Intended Use Evidence
- The product label itself — Including all text on the primary display panel, information panel, carton, and any labels affixed to the product
- Labeling (broader than label) — Any written, printed, or graphic matter accompanying the product, including package inserts, brochures, and instructions for use
- The company website — Courts have held that a company's website constitutes labeling under 21 U.S.C. § 321(m) when it promotes specific products
- Social media posts — Official company accounts promoting specific products are treated as labeling
- Online retail listings — Amazon, eBay, and other marketplace listings under the company's control
- Promotional materials — Brochures, trade show materials, sales representative scripts, testimonials the company amplifies
- Oral statements by company representatives — What sales reps say to customers can establish intended use
- The circumstances of sale — Where and how a product is sold can establish intended use (e.g., selling a substance only to bodybuilders suggests performance-enhancing intended use)
The "We Just Sell the Ingredient" Defense Doesn't Work. A common client attempt to avoid drug classification: "Our label doesn't say it treats anything — we just sell turmeric extract." FDA's response: if you know or have reason to know that your product is being used as a drug — because of your marketing, your target customer, your distributor's claims, or your own prior statements — that knowledge can establish intended use regardless of what the current label says. Always look at the entire commercial context, not just the physical label.
The Classification Decision Tree
Use this systematic framework to classify any FDA-regulated product. Work through each question in order — the first "yes" answer that leads to a definitive category terminates the analysis.
Check: Is there a recognized disease, disorder, or condition being referenced? Does the claim suggest the product affects that condition?
Key distinction: A moisturizer "hydrates skin" (appearance only = cosmetic). A moisturizer "stimulates collagen synthesis at the cellular level" (affects body structure = drug).
Software as a Medical Device (SaMD): Software that meets the device definition — including AI/ML diagnostic tools — is regulated as a device under 21 U.S.C. § 321(h). This is one of the fastest-growing device subcategories.
Important: a product can be simultaneously a cosmetic and a drug if it has both appearance-related and structure/function effects. Sunscreen with SPF = cosmetic + OTC drug. Shampoo that also controls dandruff = cosmetic + OTC drug.
The Six FDA Product Categories — Side by Side
Medical Device Classification in Depth
Device classification has its own internal system — the three-class framework established by the Medical Device Amendments (1976). Every device type has a specific product code assigned by CDRH, which determines its class and regulatory pathway. Before advising any device client, you must identify the product code.
- Bandages and wound dressings
- Tongue depressors
- Elastic bandages
- Non-powered hand surgical instruments
- Manual stethoscopes
- Non-measuring examination gloves
- Crutches and walkers (basic)
- Blood pressure monitors
- Digital X-ray systems
- Powered wheelchairs
- Pregnancy test kits
- Contact lenses and solutions
- Hearing aids (most types)
- Infusion pumps
- Surgical drapes and gowns
- Implantable cardiac pacemakers
- Cochlear implants
- Silicone gel-filled breast implants
- Ventricular assist devices
- Total artificial hearts
- Implantable neurostimulators
- Deep brain stimulators
How to Find a Device's Product Code
Every FDA-regulated device has a 3-character product code that determines its class and regulatory pathway. Finding the right product code is the first step in any device engagement.
The Gray Areas — Where Classification Gets Hard
The most intellectually demanding part of classification work is the gray zone — products where the boundary between categories is genuinely ambiguous. These situations require deep knowledge of FDA's historical positions, relevant warning letters, and often formal FDA interaction to resolve definitively.
Dual-Regulated Products — When Two Categories Apply Simultaneously
FDA explicitly recognizes that some products can be regulated as both a cosmetic and a drug simultaneously. This is one of the most practically important classification concepts because it affects labeling, manufacturing, registration, and what claims are permissible.
| Product | As Cosmetic | As OTC Drug | Compliance Needed |
|---|---|---|---|
| Dandruff shampoo (Head & Shoulders) | Cleans and conditions hair | Controls dandruff (pyrithione zinc) | Drug Facts panel + cosmetic labeling + OTC drug GMP + cosmetic facility registration |
| SPF moisturizer | Moisturizes and smooths skin | Sunscreen with SPF claim | Drug Facts panel + sunscreen monograph compliance + cosmetic and drug manufacturing standards |
| Fluoride toothpaste | Cleans teeth, freshens breath | Prevents cavities (fluoride) | Drug Facts panel + anticaries monograph + both cosmetic and drug requirements |
| Antiperspirant/deodorant | Deodorant function (cosmetic) | Reduces sweat (antiperspirant = drug) | "Antiperspirant" = OTC drug; "Deodorant only" = cosmetic. Combination products need Drug Facts. |
| Lip balm with SPF | Moisturizes lips | Sun protection (SPF claim) | Same as SPF moisturizer — dual regulated. Drug Facts required. |
| Medicated acne wash | Cleanses skin | Treats acne (benzoyl peroxide/salicylic acid) | OTC drug monograph for acne + cosmetic requirements for the cleansing function |
Dual Regulation Means Dual Compliance. When a product is both a cosmetic and an OTC drug, both sets of requirements apply simultaneously. The product must have both a Drug Facts panel (drug requirement) and comply with cosmetic labeling rules (ingredient declaration in INCI format, net quantity, distributor address). Manufacturing must comply with both OTC drug GMP and cosmetic GMP standards. The product must be registered both as an OTC drug establishment and as a cosmetic facility under MoCRA.
Getting Formal Classification from FDA
When a product genuinely doesn't fit neatly into a category, or when the stakes are high enough that you need certainty, FDA provides formal mechanisms for classification determination. These are not optional in high-stakes situations — they are essential.
FDA Product Codes — The Classification Infrastructure
Every regulated product has a 3-character FDA product code that determines its specific classification within a category. These codes appear in Prior Notice submissions, drug listings, device listings, and import entries. Knowing how to find and verify product codes is a fundamental operational skill.
| System | Purpose | URL |
|---|---|---|
| CDRH Product Classification Database | Find device product code, class, 510(k) requirement, CFR citation | accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD |
| CFSAN Product Code Builder | Find food product codes for Prior Notice and facility registration | access.fda.gov (within FURLS) |
| CDER Drug Products Database | Verify approved drug products, NDC numbers, drug listings | accessdata.fda.gov/scripts/cder/daf |
| Orange Book | Approved drug products with therapeutic equivalence evaluations (generics) | accessdata.fda.gov/scripts/cder/ob |
| Purple Book | Approved biologic products and biosimilar information | purplebooksearch.fda.gov |
| Cosmetics Direct | MoCRA cosmetic facility registration and product listing | cosmeticsdirect.fda.gov |
The Consultant's Classification Workflow
Here is the exact sequence of steps to follow when a new client brings you a product for classification. This process should be documented in writing and shared with the client — it becomes part of your engagement record and demonstrates your professional diligence.
A Product That Was Three Different Things Depending on Who Was Selling It
A Korean manufacturer produces a collagen powder product. The base product is identical — collagen peptides, vitamin C, hyaluronic acid. But three different U.S. buyers are marketing it differently:
- Buyer A (Beauty Retailer): Markets as "Beauty Collagen Supplement — Supports Skin, Hair, and Nails" → Dietary Supplement — Facility registration, Part 111 GMP, Supplement Facts panel, DSHEA disclaimer required
- Buyer B (Grocery Chain): Markets as "Collagen-Enhanced Protein Drink — Refreshing and Nutritious" in a ready-to-drink format → Conventional Food — Facility registration, Part 117 GMP, Nutrition Facts panel, standard food labeling required
- Buyer C (Medical Channel): Markets as "Clinically Proven Joint Repair Formula — Reduces Arthritis Pain" → Unapproved Drug — Cannot be marketed without NDA. Period. All prior work by the manufacturer is irrelevant. The U.S. buyer is the responsible party for the illegal claim.
The Korean manufacturer's facility registration as a food facility (obtained for Buyer A and B) provides no protection for Buyer C's illegal drug claims. Each buyer's commercial presentation creates its own classification reality.
The Consequences of Getting Classification Wrong
Understanding the stakes makes you a better advocate for your classification work. When you tell a client their label must change before import, you're not being bureaucratic — you're preventing the following:
| Scenario | Immediate Consequence | Longer-Term Consequence |
|---|---|---|
| Food sold with drug claim (unregistered drug) | Automatic import detention or refusal at U.S. border | Import alert against the facility; potential seizure of all U.S. inventory; criminal referral |
| Device marketed beyond cleared use | Warning letter from CDRH; shipments flagged for examination | Potential import alert; recall of devices making unauthorized claims; PMA required if device reclassified |
| Supplement making disease claims | Warning letter; product treated as unapproved new drug | Import alert; seizure; injunction against distribution; criminal prosecution of responsible officers |
| Cosmetic making drug claims | Warning letter; product reclassified as unapproved drug | All manufacturing must meet drug GMP; product cannot be sold until compliance achieved; potential import detention |
| Drug filed as food (under-registration) | Drug enters market without required approval — strict liability violation | Seizure; injunction; criminal prosecution; permanent reputational damage; responsible corporate officer personally liable |
- Classification is determined by intended use — not by ingredients, not by physical form, not by country of origin. The same compound marketed differently can be food, drug, supplement, or cosmetic. The intended use doctrine under 21 U.S.C. § 321(g)(1) is the master principle.
- Intended use is established from the entire commercial presentation — label, labeling, website, social media, marketplace listings, and oral statements by representatives. Cleaning up the physical label while leaving disease claims on a website is not a solution.
- The six-step classification decision tree provides a systematic framework: (1) disease claim? → drug; (2) structure/function claim? → drug or supplement; (3) physical mechanism? → device; (4) ingested? → food or supplement; (5) applied externally for appearance? → cosmetic; (6) for animals? → veterinary pathway.
- Device classification uses a three-class system: Class I (most exempt from 510(k)), Class II (most require 510(k) clearance), Class III (require PMA or De Novo). Always confirm device product code using CDRH's Product Classification Database before advising a device client.
- Dual-regulated products (cosmetic + drug) are common and require simultaneous compliance with both regulatory frameworks — Drug Facts panel, OTC drug GMP, and cosmetic labeling and registration all apply at the same time.
- When classification is genuinely ambiguous, use formal mechanisms: Request for Designation (OCP) for combination products, Q-Sub meetings (CDRH) for devices, Pre-IND meetings (CDER) for drugs. These are free and produce written FDA guidance.
- Always document your classification analysis in a written memo with CFR and USC citations. This protects you professionally, guides the client, and establishes a clear record of due diligence.
Need your product classified by FDA regulatory experts?
Regovant provides written product classification assessments with full legal citations, pathway identification, and a clear compliance roadmap — before you spend a dollar on registration or application fees.